Autoantibodies targeting ficolin-2 in systemic lupus erythematosus patients with active nephritis - Groupe Réponse immunitaire aux pathogènes et au soi altéré / Immune Response to Pathogens and altered-self Group (IBS-IRPAS) Accéder directement au contenu
Article Dans Une Revue Arthritis Care & Research = Arthritis Care and Research Année : 2018

Autoantibodies targeting ficolin-2 in systemic lupus erythematosus patients with active nephritis

Sophie Colliard
  • Fonction : Auteur
  • PersonId : 1024381
Alban Deroux
  • Fonction : Auteur
  • PersonId : 964950
Nathalie Bardin
Laurence Bouillet
  • Fonction : Auteur
  • PersonId : 834291
Nicole M. Thielens

Résumé

Objective: Systemic lupus erythematosus (SLE) is a multi‐system inflammatory disease characterized by production of various autoantibodies. The aim of this study was to investigate the presence of anti‐ficolin‐2 antibodies in SLE patients and to evaluate the association between the levels of these autoantibodies, clinical manifestations, and disease activity. Methods: This is a comparative study using a cohort of 165 SLE patients and 48 healthy subjects. SLE patients were further divided into two groups, with “low disease activity” (SLEDAI score ≤ 4, n = 88) and with “high disease activity” (SLEDAI score > 4, n = 77). Clinical manifestations were defined according to the physician in charge. Active lupus nephritis (LN) was documented by kidney biopsy. Detection of anti‐ficolin‐2 antibodies was performed by ELISA. Results: Levels of the anti‐ficolin‐2 autoantibodies were significantly higher in SLE patients as compared to healthy subjects and associated with the SLEDAI score. They were found positive in 61/165 (37%) SLE patients. Presence of anti‐ficolin‐2 antibodies was significantly related only to renal involvement, with a very high prevalence (86%) of anti‐ficolin‐2 antibodies in SLE patients with active LN. Patients with active proliferative LN had significantly more positive anti‐ficolin‐2 antibodies than those with non‐proliferative LN. The combination of anti‐ficolin‐2, anti‐ficolin‐3 and anti‐C1q demonstrated a very high specificity (98%) for the diagnosis of active LN. Conclusion: Our results support the usefulness of anti‐ficolin‐2 as a complementary serological biomarker for the diagnosis of active lupus with renal manifestation
Fichier principal
Vignette du fichier
Colliard_et_al-2017-Arthritis_Care_&_Research.pdf (557.75 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-01696101 , version 1 (24-05-2018)

Identifiants

Citer

Sophie Colliard, Noemie Jourde-Chiche, Giovanna Clavarino, Françoise Sarrot-Reynauld, Evelyne Gout, et al.. Autoantibodies targeting ficolin-2 in systemic lupus erythematosus patients with active nephritis. Arthritis Care & Research = Arthritis Care and Research, 2018, ⟨10.1002/acr.23449⟩. ⟨hal-01696101⟩
1874 Consultations
257 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More